AMN107, novel aminopyrimidine inhibitor of Bcr-Abl, is significantly more potent than imatinib mesylate against Philadelphia chromosome positive acute lymphoblastic leukemia cells.

被引：0
|
作者：
Golemovic, M
Beran, M
Giles, F
Manshouri, T
Thomas, D
Cortes, J
Manley, P
Alland, L
Rae, P
Dugan, M
Estrov, Z
Arlinghaus, RB
Kantarjian, H
Verstovsek, S
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Novartis Pharmaceut, Basel, Switzerland
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2737
引用
收藏
页码：748A / 748A
页数：1
相关论文
共 50 条
  • [21] Mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
    Platanias, Leonidas C.
    LEUKEMIA & LYMPHOMA, 2011, 52 : 2 - 3
  • [22] A NOVEL 203 KD ABERRANT BCR-ABL PRODUCT IN A GIRL WITH PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA
    INUKAI, T
    SUGITA, K
    SUZUKI, T
    IJIMA, K
    GOI, K
    TEZUKA, T
    KOJIKA, S
    HATAKEYAMA, K
    KAGAMI, K
    MORI, T
    OKAZAKI, T
    MIZUTANI, S
    NAKAZAWA, S
    BRITISH JOURNAL OF HAEMATOLOGY, 1993, 85 (04) : 823 - 825
  • [23] Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation
    Radich, J
    Gehly, G
    Lee, A
    Avery, R
    Bryant, E
    Edmands, S
    Gooley, T
    Kessler, P
    Kirk, J
    Ladne, P
    Thomas, ED
    Appelbaum, FR
    BLOOD, 1997, 89 (07) : 2602 - 2609
  • [24] A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP).
    Kantarjian, H. M.
    Gattermann, N.
    O'Brien, S. G.
    Bhalla, K.
    Hochhaus, A.
    Cervantes, F.
    Alland, L.
    Ottmann, O.
    Giles, F.
    Le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 345S - 345S
  • [25] Safety, pharmacokinetics (PK), metabolism, and mass balance of [14C]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects.
    Kagan, M
    Tran, P
    Fischer, V
    Savage, P
    Smith, T
    Tanaka, C
    Schran, H
    Narurkar, M
    Alland, L
    BLOOD, 2005, 106 (11) : 302B - 302B
  • [26] The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
    Maekawa, Taira
    Ashihara, Eishi
    Kimura, Shinya
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (05) : 327 - 340
  • [27] The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
    Taira Maekawa
    Eishi Ashihara
    Shinya Kimura
    International Journal of Clinical Oncology, 2007, 12 : 327 - 340
  • [28] Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
    Elias, Marjanu Hikmah
    Baba, Abdul Aziz
    Husin, Azlan
    Abdullah, Abu Dzarr
    Hassan, Rosline
    Sim, Goh Ai
    Wahid, S. Fadilah Abdul
    Ankathil, Ravindran
    HEMATOLOGY REPORTS, 2012, 4 (04) : 86 - 90
  • [29] Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against unmutated or mutant Bcr-Abl-expressing human leukemia cells.
    Fiskus, W.
    Pranpat, M.
    Balasis, M.
    Atadja, P.
    Manley, P.
    Giles, F.
    Bhalla, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 359S - 359S
  • [30] Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance
    Hantschel, Oliver
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (02): : 157 - 159
12345